Journal of Bioequivalence & Bioavailability

An anthology of various strategies to overcome the barriers of oral bioavailability

2^nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

06-08 June 2011, Las Vegas, USA

Kanchan Kohli

Scientific Tracks Abstracts: JBB

Abstract:

I n today�s drug development world, combinatorial chemistry, high-throughput screening and genomics have provided a technologic platform that produces hundreds of thousands of new chemical entities with therapeutic potential each year. Oral bioavailability plays leading role in primary screening of drug and designing innovative drug delivery technologies. Th e therapeutic eff ectiveness of a drug depends upon the ability of the dosage form to deliver the medicament to its site of action at a rate and amount suffi cient to elicit the desired pharmacodynamic response. Nearly 60% of the herbal, synthetic and biotechnological drug candidates face bioavailability problems therefore dosage form design becomes an imperative tool. Initial insilico and invitro predictive methods for understanding factors infl uencing bioavailability exclusively focused on drug characteristics thus overlooked action of transporter protein, presystemic metabolism, Pgp effl ux mechanism which plays signifi cant role on absorption of drug. With the advent of novel techniques much attention should be focused in dealing with major barriers for oral absorption, as well as methods for evaluating oral bioavailability. Choosing a suitable approach among vast number of approaches is oft en not an easy task. Suffi cient survey and knowledge of the causes of low bioavailability and various absorption pathways is a key to successful selection of an appropriate strategy for a particular drug. Th erefore it is mandatory for every research to give more stress on diff erent barriers to absorption and various approaches that can be successfully applied to perk up oral bioavailability

Biography :

Dr. Kanchan Kohli, M.Pharm, Ph.D (Pharmaceutics) is presently working as an Associate Professor, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard University, New Delhi, India with an overall 35 years of experience. Her research is in collaboration with industry and is focused on development of novel drug delivery carriers of natural products for their bioavailability enhancement and targeted drug delivery. She has more than 90 research and review articles to her credit in various national and international peer reviewed journals and 10 Indian patents have been applied since 2007-2010. Recently received honor like FIP Congress Travel Grant of 2500 Euros by the Honorable Jury of 69th International Congress of FIP (International Pharmaceutical Federation), which was held at Istanbul, (Turkey), 2009